Monitor for any further reductions by Morgan Stanley or other large institutional holders. The drop below 5% removes Morgan Stanley from future 13G filing requirements, reducing transparency into their position changes.
Price Chart
How similar events traded
Executive Summary
Morgan Stanley filed an amended Schedule 13G disclosing a 4.9% beneficial ownership stake in Stoke Therapeutics as of September 30, 2026, down from above 5% in the prior filing. The filing states Morgan Stanley has ceased to be a beneficial owner of more than 5% of the class, indicating a reduction in its passive stake.
Key Financial Metrics
Key Facts
- Morgan Stanley reported beneficial ownership of 3,177,169 shares of Stoke Therapeutics common stock, representing 4.9% of shares outstanding as of September 30, 2026.
- The filing states Morgan Stanley has ceased to be the beneficial owner of more than 5% of the class of securities.
- Morgan Stanley Capital Services LLC reported 2,653,126 shares (4.1%) as a wholly-owned subsidiary.
- The filing is an amendment to Schedule 13G, indicating passive investment intent under Rule 13d-1(b).
Financial Impact
Morgan Stanley reduced its stake from above 5% to 4.9%, a decrease of at least 0.1% of shares outstanding.
Risk Factors
- Morgan Stanley's reduction below 5% could signal reduced institutional confidence, though the decrease is small.
- No specific reason for the reduction is disclosed in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000895421-26-000321 |
| Exhibit: EXHIBIT_NO.99.2.txt | 0000895421-26-000321 |
| Document: 0000895421-26-000321-index-headers.html | 0000895421-26-000321 |
| Document: 0000895421-26-000321-index.html | 0000895421-26-000321 |
| Document: 0000895421-26-000321.txt | 0000895421-26-000321 |
Track record
18 reports on STOK
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.63 Now $26.63 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.84 Now $26.63 −0.78% settles Feb 12
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $26.12 Now $26.63 +1.95% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
- Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
- Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers